Intracutaneous suture versus transcutaneous skin stapling for closure of midline or horizontal skin incision in elective abdominal surgery and their outcome on superficial surgical site infections–INTRANS: study protocol for a randomized controlled trial by Katja Maschuw et al.
TRIALS
Maschuw et al. Trials 2014, 15:25
http://www.trialsjournal.com/content/15/1/25STUDY PROTOCOL Open AccessIntracutaneous suture versus transcutaneous skin
stapling for closure of midline or horizontal skin
incision in elective abdominal surgery and their
outcome on superficial surgical site infections–
INTRANS: study protocol for a randomized
controlled trial
Katja Maschuw1*, Christine Heinz2, Elisabeth Maurer1, Alexander Reuss2, Carmen Schade-Brittinger2
and Detlef Klaus Bartsch1Abstract
Background: Surgical site infections are the third most frequent type of nosocomial infections. Evidence-based
recommendations have been given regarding preoperative hospitalization, hygiene and air-conditioning, patient
conditions, and wound dressing. However, no general recommendations concerning wound closure exist.
Systematic reviews and meta-analyses suppose a benefit of intracutaneous suture compared to skin staples in
orthopedic and obstetric surgery. Literature data for skin closure in elective abdominal surgery are still deficient.
Methods/Design: Patients scheduled for any elective abdominal surgery requiring midline or horizontal
laparotomy are potentially eligible for the trial. Trial-specific exclusion criteria are date of admission exceeding four
days prior to surgery, antibiotic treatment within the past 14 days, any previous midline or horizontal laparotomy in
case the procedure requires the same skin incision as before, neurophysiological deficits or severe psychiatric or
neurologic diseases that do not allow an informed consent or compliance, and participation in any other
interventional trial with interference of intervention and outcome. The trial is created for process innovation within
standardized surgical procedures. It is designed as a prospective randomized controlled single center trial in a
parallel design including an active comparator and an intervention group. The intervention addresses the closure of
skin after the main surgical procedure: intracutaneous suture in the intervention group and transcutaneous skin
stapling in the control group. The rate of superficial surgical site infections is defined as the primary endpoint.
Secondary endpoints are time for skin closure, satisfaction with the cosmetic outcome 30 days after surgery,
prolongation of hospital stay, and duration of sick-leave due to surgical site infections. The primary efficacy analysis
follows the intention-to-treat principle. A χ2 test will be applied.
Discussion: The trial is expected to balance the shortcomings of the current evidence. It will help to define the
gold standard for wound closure in elective abdominal surgery. Patients’ safety and quality of life are assumed to
be enhanced. Therapy costs are likely to be reduced and health care optimized.
(Continued on next page)* Correspondence: maschuw@med.uni-marburg.de
1Department of Visceral, Thoracic and Vascular Surgery, University Hospital
Giessen and Marburg GmbH–Location Marburg, Baldingerstrasse, D-35043
Marburg, Germany
Full list of author information is available at the end of the article
© 2014 Maschuw et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Maschuw et al. Trials 2014, 15:25 Page 2 of 6
http://www.trialsjournal.com/content/15/1/25(Continued from previous page)
Trial registration: German Clinical Trials Register (DRKS) DRKS00004542.
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The prevention of surgical site infections is one of the
basic issues in the study of any surgical discipline to
enhance quality of health care and patient safety. Over
the past decades, this attempt led to the constitution of
national institutes for disease surveillance and preven-
tion. For diagnostic purposes, an internationally ac-
knowledged classification for surgical site infections has
been outlined by the Center of Disease Control (CDC),
Atlanta, USA, within a guideline for prevention in 1999.
According to their location and source, surgical site
infections are categorized by severity and implications.
In Germany, CDC-criteria were adopted by the National
Institution for Disease Surveillance and Prevention
(Robert Koch Institute) and implemented within the Na-
tional Reference Center for Surveillance of Nosocomial
Infections [1]. A national representative prevalence study
(NIDEP-1-trial) demonstrated surgical site infections to
be the third most frequent type of nosocomial infections
with an incidence of 16% [2], affecting 128,000 patients
per year [3] and with a prolonged hospital stay ranging
between 9.5 to 23.7 days [4]. Besides patient safety and
quality of life, postoperative surgical site infections are
of economic relevance, since hospital treatment costs in-
crease by 2.8-fold on average [3]. For example, in the
USA, the total economic load due to nosocomial infec-
tions was calculated to have reached 95 million USD in
1992 [3].
The main source for surgical site infections is the pa-
tients’ own flora, which despite evidence-based pre-
operative antisepsis, still causes endogenous infections
with a proportion of 90% compared to 10% of exogenous
infections due to contamination by any external agent
[5]. In systematic reviews, meta-analyses, and random-
ized controlled trials, the length of hospitalization, anti-
sepsis of patient’s skin, surgeons’ hands, operation site,
depilation, air-conditioning of the operation room, pa-
tient’s temperature, and wound drainage and dressing
have proven to be influential in wound healing. Subse-
quently, standards and recommendations have been out-
lined by national surveillance institutions [6]. However,
no general recommendation for the technique of skin
closure exists to date. Staples and different types of su-
tures are used in clinical routine. Alternatively, adhesive
stripes and tissue adhesive DERMABOND ProPen® and
Op-site® films are especially favored to close small inci-
sions [7,8]. Results of randomized controlled trialsassessing the impact of different closure techniques on
superficial surgical site infections are conflicting in de-
pendence of body region and surgical procedure. Differ-
ences in the bacterial spectrum and number of bacteria
are likely to be influential. In orthopedic surgery, a
meta-analysis comparing the outcome of sutures versus
staples on superficial surgical site infections demon-
strated superiority of sutures for knee and hip surgery.
However, the authors outlined substantial methodo-
logical limitations of the primary data and the need for
definite randomized controlled trials [9]. In heart sur-
gery, a systematic review of randomized controlled trials
for closure of leg wounds after vein graft harvesting for
coronary artery bypass surgery revealed no difference
between sutures and staples [10]. In obstetrics, a recent
systematic review and meta-analysis demonstrated the
superiority of subcuticular sutures compared to staples
for skin closure after caesarean sections; there was no
significant difference in the cosmetic outcome [11].
Regarding abdominal surgery, five randomized con-
trolled trials dating from 1981 to 1992, assessed the out-
come of staples versus sutures for skin closure on
superficial surgical site infection, pain, operation time,
and cosmetic outcome. Three of the trials compared
interrupted mattress sutures to staples [12-14], and two
compared intracutaneous sutures versus staples [15,16],
including a comparison of different suture materials
[16]. While in the Pickford trial [14] the infection rate
was significantly lower in favor of staples (6.3% vs. 17%),
no significant difference could be demonstrated in the
trials of Eldrup [12] and Gatt [13]. The two trials com-
paring intracutaneous sutures to staples showed no sig-
nificant difference regarding the incidence of superficial
surgical site infection. Moreover, the suture material was
proven to be of no impact [16]. All trials, which add-
itionally considered the cosmetic outcome [13,15,16]
and closure time, revealed no significant difference for
the cosmetic outcome but a significant reduction of the
closure time. However, data addressing postoperative
pain were conflicting. Two trials demonstrated a signifi-
cant reduction of postoperative pain in favor of staples
[12,15], whilst one trial showed no difference [13]. Al-
though the evidence is usually classified as “Ib” accord-
ing to the trial design, the methodology is deficient
referring to power calculation, calculation of the effect
sizes, allocation, and methods for minimizing bias and
blinding, as well as calculation of outcomes when using
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sidering the methodological progress and consolidated
standards of conducting and reporting trials within the
past two decades. A recent interdisciplinary meta-analysis
of randomized controlled trials investigating the impact
of staples versus sutures for skin closure of abdominal
wounds shares the same limitations [17]. Altogether, infec-
tion rates did not differ significantly comparing suture and
staples for skin closure and there were no significant dif-
ferences in the cosmetic outcome; the primary data were
derived from obstetrics and gynecology, general surgery,
head and neck surgery, vascular surgery, and emergency
care [17]. Despite heterogeneity having been found as not
significant, the primary data bear substantial methodo-
logical limitations.
Most of the trials above had multiple primary end-
points; neither a calculation of the effect size nor power
was reported, and suture materials and techniques var-
ied. To outbalance conflicting results and a lack of evi-
dence, prospective randomized controlled trials are
needed to define the ideal closure technique for skin in-
cisions in abdominal surgery.
Methods/Design
A retrospective analysis of in-house data has been done
to prepare the calculation of the sample size and power.
This trial manuscript was prepared thereafter. The local
ethics committee of the Philipps-University of Marburg
gave a positive approval on October 2, 2012 (leading
ethics committee number 190/12). The trial is registered
at the German Clinical Trials Register (DRKS) (trial
number DRKS00004542). Financing is granted through
an in-house funding program of the Philipps-University
Marburg and Rhoen-AG. The preparation of electronic
case report forms, database, and data management sys-
tem is established.
Eligibility
Patients scheduled for any elective abdominal surgery
requiring a midline or horizontal laparotomy are poten-
tially eligible for the present study. Surgical procedures
comprise small bowel and large bowel resection, rectal
surgery including laparoscopic assisted colorectal resec-
tions with Pfannenstiel incision exceeding six centimeters
in length, esophageal, gastric, duodenal, and pancreatic
surgery, liver resections, open cholecystectomies with or
without choledochotomies, gastro-intestinal and intestinal-
intestinal bypass anastomosis, bilio-digestive anastomosis,
and splenectomies. After a screening visit, patients will be
allocated to the trial according to the below mentioned
inclusion and exclusion criteria. Additionally, patient
specific risk factors such as age, gender, American Soci-
ety of Anesthesiologists (ASA)-status, body mass index,
diabetes, steroid intake, and smoking habits will berecorded. Before enrolment, an informed consent will
be obtained from each patient.
Inclusion criteria
Key inclusion criteria are scheduled for any elective ab-
dominal surgery using midline or horizontal laparotomy,
age greater than or equal to 18 years, expectancy of life
greater than 12 months, and informed consent.
Exclusion criteria
Exclusion criteria are date of admission exceeding four
days prior to surgery, antibiotic treatment within the
past 14 days, any previous midline or horizontal laparot-
omy if the procedure requires the same skin incision as
before, neurophysiological deficits or severe psychiatric
or neurologic diseases that do not allow an informed
consent or compliance, participation in any other inter-
ventional trial with interference of intervention and out-
come, and inability to understand patients’ information
and informed consent form.
Intervention and control
The study is designed as a prospective, randomized, con-
trolled, single center clinical trial in a parallel design in-
cluding an intervention group and an active comparator.
The intervention addresses the type of skin closure in an
elective abdominal surgery. In the intervention group, skin
closure is performed by intracutaneous suture using
Monosyn® 4-0. Skin staples are used in the control group.
After the closure of the fascia, patients are randomly
assigned to an intervention or control group by intraopera-
tive randomization. Thereafter, the length of the incision
and the thickness of the subcutaneous tissue at its thickest
point is measured and recorded. The subcutaneous wound
is prepared for closure according to the local in-house
standard: lavage with diluted chloramine (0.05%), suction
drain and closure by absorbable inverting interrupted sin-
gle stitches. The standard is maintained to control poten-
tial confounders of superficial surgical site infections.
When the intervention is applied, the time to close the skin
is measured and recorded. Further, intraoperative compli-
cations such as relevant contaminations of the abdominal
cavity which require an additional lavage, extensive blood
loss exceeding 500 ml, intraoperative cardiovascular com-
plications or resuscitations, and the total operation time
(from the skin incision to skin closure) are registered.
Either the responsible surgeon, or the first or second as-
sistant may close the skin. No special surgical expertise is
required since skin stapling and intracutaneous suture are
basic surgical skills acquired at the very beginning of surgi-
cal training or even in medical training. Altogether, 27 sur-
geons, including the head of the department, consultants,
senior and junior registrars, will participate in the study.
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Both types of skin closure–transcutaneous stapling and in-
tracutaneous suture–are considered safe and standardized
techniques in abdominal surgery. The main surgical pro-
cedures are not influenced by the trial protocol. After
surgery and closure of the abdominal wall and subcuta-
neous tissue, merely the type of skin closure will be de-
termined through randomization. The trial is designed
for process innovation within standardized therapeutic
surgical procedures in an elective setting. No new sur-
gical technique is applied.
Definition of endpoints and outcome measures
Primary endpoint
The primary endpoint is the incidence rate of superficial
surgical site infections. Superficial surgical site infection
is defined as a category A1 infection according to the
CDC, as infection of the incision within 30 days after
surgery, involving skin and subcutaneous tissue only
and meeting one of the following criteria/clinical signs:
(I) purulent secretion, cultural proof of bacteria derived
from the tissue covering the incision or any secretion
from the incision; (II) pain or tenderness, swelling,
redness, warmth; (III) opening of the wound by the
treating surgeon; and (IV) diagnosis made by the treat-
ing medical doctor.
Type A2 infections are defined as infections within 30
days after surgery and most probably linked to the previ-
ous surgical procedure, involving fascia and muscle, and
meeting one of the following criteria: (I) purulent secre-
tion from the depth of the incision but not from the
organ or visceral cavity; (II) spontaneously opened or
opened by a surgeon in case of at least one of the follow-
ing symptoms: fever (>38°C), localized pain, or localized
tenderness; (III) abscess or other signs of infection in-
volving deep tissue layers during another surgery re-
vealed by histopathology or radiology; and (IV) diagnosis
made by the treating medical doctor.
Type A3 infections imply infections within 30 days
after surgery and most probably linked to the previous
surgical procedure and involving the visceral cavity ad-
dressed within the previous surgery and meeting one of
the following criteria: (I) purulent secretion from a drain
addressing the organ or cavity on which the previous
surgery was performed; (II) cultural proof of bacteria of
a septic secret, organ or cavity; (III) abscess or other
signs of infection of the organ or visceral cavity within
the clinical examination, subsequent surgery, histopath-
ology, or radiology; and (IV) diagnosis made by the
treating medical doctor.
Depending on fulfillment of these criteria, the surgical
site infection is assigned to one of the three different cat-
egories A1–3, or in case of no infection, “none”. The
wound is photodocumented by an independent woundmanager on days 2, 5, 10, and 30 after surgery. In case of
documented A1–3 infections, the subsequent treatment
or procedure is additionally recorded. Category A2 or A3
infections which emerge from deeper layer or even the ab-
dominal cavity and which are not linked to an infection of
the upper layer of the skin are not attributed to the
method of skin closure and thus do not attribute as fail-
ures to the statistical analysis of the primary endpoint.
Secondary endpoints
Secondary endpoints comprise time of skin closure, satis-
faction of the cosmetic outcome 30 days after surgery,
prolongation of hospital stay, and inability to work due to
surgical site infections. After randomization and closure
of the subcutaneous tissue, the time of skin closure is re-
corded. Within the follow-up visits, the satisfaction of the
cosmetic outcome 30 days after surgery is assessed separ-
ately by the patient and an independent wound manager
on a scale as used within the German school grade system
(1 = best to 6 = worst). Moreover, the prolongation of hos-
pital stay and employees’ illness due to surgical site infec-
tions are recorded.
Randomization, allocation concealment, and blinding
A random sequence will be generated through computer-
ized random assignment and concealed allocation. Intra-
operative randomization will be performed. After closure
of the fascia, the anesthetist or the second scrub nurse
calls the randomization office to give the patient’s number,
surgeon’s name, and ask for allocation. Using the loud-
speaker, the surgeon then is de-blinded. The outcome as-
sessment cannot be blinded due to the nature of the
study. Therefore, the detection bias is high and cannot be
minimized. Skin staples will be visible for the outcome as-
sessors during the follow-up visits from days 1 to 10.
Sample size
The trial is designed on the basis of a critical appraisal of
current evidence. Literature data concerning the evalu-
ation of intracutaneous suture and skin stapling with re-
gard to superficial surgical site infections are insufficient.
Retrospective data of the own clinic served as reference
for calculating the sample size. The standard procedure
for skin closure has changed during the past years, i.e., in
2011, the patients routinely received intracutaneous su-
ture, while in 2009, the patients had routinely received
skin stapling. Retrospective analysis of these data showed
a lower rate of A1 infections for intracutaneous (4%) than
for stapling (14%) closure. To achieve a power of 80%, 128
patients per group are needed to detect this difference
when applying a two-sided χ2 test with a significance level
of 5%. Incorporating a rate of drop-outs of 10%, a total of
285 patients need to be randomized.
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The primary hypothesis is that the rate of superficial surgi-
cal site infections within 30 days after elective abdominal
surgery via midline or horizontal incision is lower in pa-
tients after intracutaneous closure of the skin when com-
pared to closure of the skin by staples. The primary
efficacy endpoint will be assessed as a rate, defined as the
number of patients who experienced a superficial surgical
site infection (type A1) within 30 days after surgery di-
vided by the number of all patients randomized to this
arm. Infections of types A2 or A3 are not defined as pri-
mary events. For the intention-to-treat analysis, these pa-
tients will be considered within the denominator. The
primary analysis will be done in the intent-to-treat popula-
tion. To compare the incidence rates in both arms, a two-
sided χ2 test will be applied. As sensitivity analyses, a χ2
test for the per-protocol population will be applied as well
as logistic regression analyses adjusting for potential prog-
nostic factors: diagnosis and procedure, age, gender, ASA-
status, body mass index, diabetes, steroid intake, smoking,
and thickness of subcutaneous fat. The secondary efficacy
endpoints will be analyzed exploratively. Appropriate
summary measures for the empirical distributions as well
as two-sided 95% confidence intervals and P values will be
reported. The safety analysis will be applied to the safety
population comprising all patients operated.
Discussion
Surgical site infections are the third most common type
of nosocomial infections. National health surveillance
systems give evidence-based recommendations for their
prevention and treatment. However, no general recom-
mendation can be given for the closure of skin in elect-
ive abdominal surgery. To date, literature data are
deficient. A retrospective in-house data analysis and a
systematic review and meta-analysis for skin closure
after cesarean sections in obstetrics lead to the conclu-
sion that intracutaneous skin closure may reduce the
incidence of superficial surgical site infections. A pro-
spective randomized clinical trial will help to define the
gold standard for skin closure in elective abdominal
surgery. A lower incidence of superficial surgical site
infections will reduce nosocomial infections, enhance
the quality of health care and patient safety, and will be
of economic relevance.
Trial status
Enrolment started on 4th March 2013.
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